Tech Center 1600 • Art Units: 1625
This examiner grants 67% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17271981 | METHODS OF DETERMINING TREATMENT CONSISTING OF RADIATION THERAPY AND/OR ALKYLATING CHEMOTHERAPY IN PATIENTS SUFFERING FROM CANCER | Non-Final OA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 17833095 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | Final Rejection | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18210992 | MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES | Final Rejection | The General Hospital Corporation |
| 18037751 | INHIBITORS OF IGF2BP1-RNA BINDING | Non-Final OA | THE PENN STATE RESEARCH FOUNDATION |
| 18249321 | STRUCTURED SURFACTANT BLEND AND SULFATE-FREE AQUEOUS PERSONAL CLEANSING COMPOSITION PREPARED THEREOF | Final Rejection | RHODIA OPERATIONS |
| 18489722 | THERAPEUTIC AGENT FOR SOLID CANCERS, WHICH COMPRISES AXL INHIBITOR AS ACTIVE INGREDIENT | Non-Final OA | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION |
| 18030865 | STAT DEGRADERS AND USES THEREOF | Non-Final OA | Kymera Therapeutics, Inc. |
| 17263135 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | Non-Final OA | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. |
| 18272419 | INDUCERS OF SENESCENCE, IN COMBINATION WITH A SELECTIVE DEATH RECEPTOR 5 (DR5) AGONIST, FOR USE IN A METHOD OF TREATING CANCER | Non-Final OA | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
| 18548678 | USE OF DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS TO TARGET FERROPTOSIS IN CANCER THERAPY | Non-Final OA | KADMON CORPORATION LLC |
| 17904404 | DRG-MDM2-5 FOR USE AS A NOVEL MOUSE DOUBLE MINUTE 2 (MDM2) INHIBITOR | Final Rejection | ISTANBUL TEKNIK UNIVERSITESI |
| 18253503 | 2,3-DIHYDRO-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Non-Final OA | Abbisko Therapeutics Co., Ltd. |
| 18552326 | PREPARATION OF 2-CHLORO-4-FLUORO-5-NITROBENZOIC ACID | Non-Final OA | ADAMA AGAN LTD. |
| 18287170 | BENZOTHIAZOLE AND QUINOLINE DERIVATIVES FOR USE IN TREATING KAWASAKI DISEASE | Non-Final OA | Shanghai Yao Yuan Biotechnology Co., Ltd. |
| 18549412 | METHOD FOR PREPARING AMIDINES | Non-Final OA | VERSALIS S.P.A. |
| 18548798 | METHODS FOR TREATING FAMILIAL CHYLOMICRONEMIA SYNDROME | Non-Final OA | AMRYT PHARMACEUTICALS INC. |
| 17639279 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | Final Rejection | HiberCell, Inc. |
| 17771391 | PROTEIN KINASE INHIBITORS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISEASES | Non-Final OA | Xavier University of Louisiana |
| 18033608 | METHOD FOR SELECTIVELY SYNTHESIZING 3,6'-DITHIOPOMALIDOMIDE FROM POMALIDOMIDE | Final Rejection | Aevis Bio, Inc. |
| 18250012 | PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES | Non-Final OA | Chulalongkorn University |
| 17790038 | PHARMACEUTICAL COMBINATION FOR TREATING TUMORS AND APPLICATION THEREOF | Non-Final OA | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD |
| 17735271 | COMPOSITIONS AND METHODS OF USING NMDAR INHIBITORS AND KINASE INHIBITORS TO TREAT LIVER CANCER | Final Rejection | Centre for Oncology and Immunology Limited |
| 17274948 | PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) INHIBITORS AND USES THEREFOR | Final Rejection | Eirion Therapeutics, Inc. |
| 17430210 | METHODS FOR TREATING CHOLESTASIS | Non-Final OA | MIRUM PHARMACEUTICALS, INC. |
| 17421980 | ANTI-CANCER COMPOSITIONS AND METHODS OF USE | Final Rejection | University of New Orleans |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy